Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 6

Safety and efficacy of tazarotene foam for the treatment of acne vulgaris

Authors Epstein EL, Gold LS

Received 2 April 2013

Accepted for publication 15 April 2013

Published 14 May 2013 Volume 2013:6 Pages 123—125


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Erica L Epstein, Linda Stein Gold

Henry Ford Hospital, Detroit, MI, USA

Background: Tazarotene foam is the first topical retinoid foam approved for the treatment of acne vulgaris.
Objective: To review the safety and efficacy studies of tazarotene foam in the treatment of moderate to severe acne.
Methods: Five Phase I safety studies in normal controls are reviewed and two Phase III safety and efficacy studies in patients with moderate to severe acne are reviewed.
Conclusion: Tazarotene foam, 0.1% was effective in the treatment of moderate to severe acne vulgaris with an acceptable tolerability profile. This treatment provides a cosmetically favorable alternative for topical retinoid therapy.

Keywords: tazarotene, acne, foam, topical retinoid

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]